WO2002000275A1 - Bio-compatible polymeric materials - Google Patents
Bio-compatible polymeric materials Download PDFInfo
- Publication number
- WO2002000275A1 WO2002000275A1 PCT/GB2001/002786 GB0102786W WO0200275A1 WO 2002000275 A1 WO2002000275 A1 WO 2002000275A1 GB 0102786 W GB0102786 W GB 0102786W WO 0200275 A1 WO0200275 A1 WO 0200275A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- moieties
- iii
- support material
- porous layer
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 172
- 229920000642 polymer Polymers 0.000 claims abstract description 161
- 238000000034 method Methods 0.000 claims abstract description 72
- 239000011148 porous material Substances 0.000 claims abstract description 33
- 239000002904 solvent Substances 0.000 claims abstract description 22
- 239000004696 Poly ether ether ketone Substances 0.000 claims abstract description 12
- 229920002530 polyetherether ketone Polymers 0.000 claims abstract description 12
- 239000012530 fluid Substances 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 229920001652 poly(etherketoneketone) Polymers 0.000 claims abstract description 3
- 239000002243 precursor Substances 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 239000002872 contrast media Substances 0.000 claims description 15
- 229920001519 homopolymer Polymers 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 229920001643 poly(ether ketone) Polymers 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229920001400 block copolymer Polymers 0.000 claims description 5
- 230000009477 glass transition Effects 0.000 claims description 5
- 229920005604 random copolymer Polymers 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 229920006125 amorphous polymer Polymers 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 230000010354 integration Effects 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 238000005187 foaming Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 125000001174 sulfone group Chemical group 0.000 claims description 2
- 150000003568 thioethers Chemical group 0.000 claims 1
- 239000006260 foam Substances 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 4
- 238000001556 precipitation Methods 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 80
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000001117 sulphuric acid Substances 0.000 description 9
- 235000011149 sulphuric acid Nutrition 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 8
- -1 hydroxy, amino Chemical group 0.000 description 8
- 229920004695 VICTREX™ PEEK Polymers 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000001569 carbon dioxide Substances 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920002492 poly(sulfone) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241001082241 Lythrum hyssopifolia Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 125000005442 diisocyanate group Chemical group 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000003754 machining Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000002459 porosimetry Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010128 melt processing Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000010883 osseointegration Methods 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920001470 polyketone Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000004736 wide-angle X-ray diffraction Methods 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
Definitions
- This invention relates to bio-compatible polymeric materials and particularly, although not exclusively, relates to a method of making a medical device, for example a prosthesis or part thereof using such a material and such a device per. se.
- bio-compatible materials do not exist passively when introduced into human or animal bodies but become integrated, for example osseo-integrated therewith.
- materials which have optimum physical (e.g. strength, modulus, wear resistance) and chemical (e.g. chemical stability, bio-stability, bio- compatibility) properties which are readily integratable with human or animal body tissues.
- a method of making a medical device or part thereof including the step of forming a porous layer on the outside of a support material, wherein said porous layer includes a polymer having a moiety of formula
- phenyl moieties in units I, II, and III are independently optionally substituted and optionally cross- linked; and wherein m,r,s,t,v,w and z independently represent zero or a positive integer, E and E' independently represent an oxygen or a sulphur atom or a direct link, G represents an oxygen or sulphur atom, a direct link or a -O-Ph-0- moiety where Ph represents a phenyl group and Ar is selected from one of the following moieties (i)*, (i)**, (i) to (x) which is bonded via one or more of its phenyl moieties to adjacent moieties
- the invention extends to a method of making a medical device or part thereof, the method including the step of forming a porous layer on the outside of the support material from a polymer having moieties I, II and/or III as described.
- any alkyl, akenyl or alkynyl moiety suitably has up to 8, preferably up to 6, more preferably up to 4, especially up to 2, carbon atoms and may be of straight chain or, where possible, of branched chain structure.
- methyl and ethyl are preferred alkyl groups and C 2 alkenyl and alkynyl groups are preferred.
- optional substituents of an alkyl group may include halogen atoms, for example fluorine, chlorine, bromine and iodine atoms, and nitro, cyano, alkoxy, hydroxy, amino, alkylamino, sulphinyl, alkylsulphinyl, sulphonyl, alkylsulphonyl, amido, alkylamido, alkoxycarbonyl , haloalkoxycarbonyl and haloalkyl groups.
- optionally substituted alkyl groups are unsubstituted.
- Said porous layer preferably includes pores
- surface pores which open at the surface of said porous layer thereby to enable tissues to grow into the pores to aid integration of said medical device and/or part when introduced into a human or animal body.
- surface pores have a diameter of at least lO ⁇ m, preferably at least 25 ⁇ m, more preferably at least 50 ⁇ , especially at least lOO ⁇ m, although it should be appreciated that a surface may include pores having diameters which are larger or smaller than those mentioned.
- the average diameter of said surface pores is at least lO ⁇ m, preferably at least 25 ⁇ m, more preferably at least 50 ⁇ m, especially at least lOO ⁇ m.
- the average diameter may be greater than 200 ⁇ m or even greater than 300 ⁇ m.
- the average diameter may be less than 600 ⁇ m, suitably less than 500 ⁇ m, preferably less than 400 ⁇ m, more preferably less than 300 ⁇ m, especially less than 200 ⁇ m.
- the diameter may be measured using a low magnification optical microscope with scale in visual frame.
- Said porous layer preferably includes a majority of pores of at least lO ⁇ m, preferably at least 25 ⁇ m, more preferably at least 50 ⁇ m, especially at least lOO ⁇ m.
- a “majority” may mean at least 50%, suitably greater than 65%, preferably greater than 80%, more preferably greater then 95%, especially greater than 98%.
- Said porous layer may have a density of at least 400 mg.cm "3 , preferably at least 500 mg.cm "3 , more preferably at least 600 mg.cm "3 . Said density may be 1000 mg.cm "3 or less.
- Said porous layer may have an average porosity of at least 20%, suitably at least 30%, preferably at least 40%, more preferably at least 50%.
- the porosity may be less than 90%, suitably less than 80%, preferably less than 70%. In some cases, the porosity may be less than 60%. Porosity may be measured by any suitable technique, for example by mercury intrusion porosimetry.
- Said porous layer preferably includes pore interconnections having average diameters of at least 50 ⁇ m, for example as measured using mercury intrusion porosimetry.
- Said porous layer preferably includes a three- dimensional network of interconnected pores. Three- dimensional networks as described rarely connect through straight channels. Preferably, said porous layer includes a network of interconnected pores throughout its volume with substantially no straight paths therein longer than the diameter of the largest pore .
- Said porous layer preferably has a thickness of at least lOO ⁇ m, more preferably at least 250 ⁇ m, especially at least 500 ⁇ m.
- the thickness may be 10mm or less, preferably 5mm or less .
- a phenyl moiety may have 1,4- or 1,3-, especially 1,4-, linkages to moieties to which it is bonded.
- Said polymer may include more than one different type of repeat unit of formula I; more than one different type of repeat unit of formula II; and more than one different type of repeat unit of formula III. Preferably, however, only one type of repeat unit of formula I, II and/or III is provided.
- Said moieties I, II and III are suitably repeat units.
- units I, II and/or III are suitably bonded to one another - that is, with no other atoms or groups being bonded between units I, II, and III.
- phenyl moieties in units I, II or III are optionally substituted, they may be optionally substituted by one or more halogen, especially fluorine and chlorine, atoms or alkyl, cycloalkyl or phenyl groups.
- Preferred alkyl groups are C ⁇ _ 10 , especially C ⁇ _ 4 , alkyl groups.
- Preferred cycloalkyl groups include cyclohexyl and multicyclic groups, for example adamantyl.
- R q is selected from the group consisting of alkyls, perfluoralkyls and aryls
- Sulphonate moieties may also be preferred in some circumstances .
- said phenyl moieties are not optionally- substituted prior to formation of said porous layer. If, however, they are substituted, they are preferably substituted by moieties that can withstand injection moulding of the polymer. Phenyl moieties may be optionally-substituted (especially sulphonated) after formation of said layer as hereinafter described.
- said polymer is cross-linked, it is suitably cross-linked so as to improve its properties.
- Any suitable means may be used to effect cross-linking.
- cross-linking between polymer chains may be effected via sulphur atoms on respective chains.
- said polymer is not optionally cross-linked as described.
- the respective phenylene moieties may independently have 1,4- or 1,3-linkages to the other moieties in the repeat units of formulae II and/or III.
- said phenylene moieties have 1,4- linkages.
- the polymeric chain of the polymer does not include a -S- moiety.
- G represents a direct link.
- a represents the mole % of units of formula I in said polymer, suitably wherein each unit I is the same;
- "b” represents the mole % ⁇ of units of formula II in said polymer, suitably wherein each unit II is the same;
- "c” represents the mole % of units of formula III in said polymer, suitably wherein each unit III is the same.
- " a is “ in the range 45-100, " more preferably in the range 45-55, especially in the range 48-52.
- the sum of b and c is in the range 0-55, more preferably in the range 45-55, especially in the range 48- 52.
- the ratio of a to the sum of b and c is in the range 0.9 to 1.1 and, more preferably, is about 1.
- the sum of a, b and c is at least 90, preferably at least 95, more preferably at least 99, especially about 100.
- said polymer consists essentially of moieties I, II and/or III.
- Said polymer may be a homopolymer having a repeat unit of general formula
- A, B, C and D independently represent 0 or 1 and E,E',G,Ar,m,r,s,t,v,w and z are as described in any statement herein.
- said polymer may be a homopolymer having a repeat unit of general formula
- A, B, C, and D independently represent 0 or 1 and E, E', G, Ar, m, r, s, t, v, w and z are as described in any statement herein.
- m is in the range 0-3, more preferably 0-2, especially 0-1.
- r is in the range 0-3, more preferably 0-2, especially 0-1.
- t is in the range 0-3, more preferably 0-2, especially 0-1.
- s is 0 or 1.
- v is 0 or 1.
- w is 0 or 1.
- z is 0 or 1.
- said polymer is a homopolymer having a repeat unit of general formula IV.
- Ar is selected from the following moieties
- the middle phenyl may be 1,4- or 1,3- substituted.
- (xv) is selected from a 1,2-, 1,3-, or a 1,5- moiety
- (xvi) is selected from a 1,6-, 2,3-, 2,6- or a 2,7- moiety
- (xvii) is selected from a 1,2-, 1,4-, 1,5- , 1,8- or a 2,6- moiety.
- One preferred class of polymers does not include any moieties of formula III, but suitably only includes moieties of formulae I and/or II.
- said polymer is a homopolymer or random or block copolymer as described, said homopolymer or copolymer suitably includes a repeat unit of general formula IV.
- Such a polymer may, in some embodiments, not include any repeat unit of general formula V.
- Suitable moieties Ar are moieties (i)*, (i) , (ii) ,
- polymers which consist essentially of phenyl moieties in conjunction with ketone and/or ether moieties. That is, in the preferred class, the polymer does not include repeat units which include -S-, -S0 2 - or aromatic groups other than phenyl .
- Preferred polymers of the type described include :
- B represents 0 (i.e. polyetherketone) ;
- E' represent oxygen atoms
- G represents a direct link
- m represents 0, w represents 1, r represents 0, s represents 1 and
- a and B represent 1. (i.e. polyetherketoneetherketoneketone) .
- polymers described in (a) and (b) are preferred, with the polymer described in (a) being especially preferred.
- the glass transition temperature (T g ) of said polymer may be at least 135°C, suitably at least 150°C, preferably at least 154°C, more preferably at least 160°C, especially at least 164°C. In some cases, the Tg may be at least 170°C, or at least 190°C or greater than 250°C or even
- Said polymer may have an inherent viscosity (IV) of at least 0.1, suitably at least 0.3, preferably at least 0.4, more preferably at least 0.6, especially at least 0.7
- RV reduced viscosity
- both RV and IV both suitably employ a viscometer having a solvent flow time of approximately 2 minutes .
- the main peak of the melting endotherm (Tm) for said polymer (if crystalline) may be at least 300°C.
- said polymer has at least some crystallinity or is crystallisable.
- the existence and/or extent of crystallinity in a polymer is preferably measured by wide angle X-ray diffraction, for example as described by Blundell and Osborn (Polymer 24, 953, 1983) .
- crystallinity may be assessed by Differential Scanning Calorimetry (DSC) .
- Said polymer may have a number average molecular weight in the range 2000-80000. Preferably said molecular weight is at least 14,000. The molecular weight may be less than 60,000.
- Said porous layer may include one or more fillers for providing desired properties.
- Said porous layer preferably incorporates an X-ray contrast medium. Fillers and/or said
- X-ray contrast medium is/are preferably distributed substantially uniformly throughout said porous layer.
- an X-ray contrast medium suitably comprises less than 25wt%, preferably "less-"than 20wt%, more preferably less than 15wt%, especially less than 10wt% of said porous layer. Where it is provided, at least 2wt% may be included.
- Preferred X-ray contrast mediums are particulate and preferably are inorganic. They preferably have low solubility in body fluids. They preferably also have a sufficient density compared to that of the polymeric material to create an image if a compounded mixture of the polymer and contrast medium are X-ray imaged. Barium sulphate and zirconium oxide are examples of X-ray contrast media. Said particulate material is suitably physically held in position by entrapment within the porous layer.
- the pore size and density of a said porous layer can be a function of the X-ray contrast medium and/or other fillers present.
- the resultant pores are predominantly in the range 30 to 60 ⁇ m, whereas at 10% filler level, the pores are predominantly in the range 70 to 120 ⁇ m.
- Said support material may be made out of any suitable material for example a metal or plastics material.
- said support material comprises a polymer which preferably includes a moiety of formula I and/or a moiety of formula II and/or a moiety of formula
- Said polymer of the support material may have any feature of the polymer in said porous layer except, preferably, said support material has lower porosity compared to the porous layer and preferably is substantially non-porous.
- Said support material and said porous layer may include the same material or a different material , but preferably both materials include phenyl moieties, carbonyl and/or sulphone moieties, and ether or
- said support material preferably includes moieties I, II and/or III and the preferred polymers which include moieties I, II and III described above with reference to the porous layer are preferred for said support material, phenyl groups of said moieties are preferably not optionally-substituted or cross-linked.
- said support material comprises any of the polymers described in paragraphs (a) to (e) above and, of these, the polymers in (a) and (b) are preferred with the polymer in (a) being especially preferred.
- Said support material preferably comprises a major amount of said polymer.
- said support material comprises more than one polymer having moieties I, II and/or III the sum of the amounts of respective said polymers preferably represents a major amount.
- a “major” amount may mean greater than 50wt%, suitably greater than 65wt%, preferably greater than 80wt%, more preferably greater than 95wt%, especially greater than 98wt% of the referenced material is present relative to the total weight of relevant material present.
- Said support material preferably comprises a unitary arrangement. That is, it preferably does not comprise a series of layers of material or include areas thereof having a higher concentration of one component compared to another.
- Said support material preferably has a thickness in at least one region thereof of at least 5mm, preferably at least 10mm, more preferably at least 20mm.
- Said support material preferably does not consist of a coating
- Said support material suitably has a tensile strength
- the tensile strength may be less than 360, suitably less than 250, preferably less than 140 MPa. It preferably has an elongate at break (according to ISO R527) of at least 40, preferably at least 50%. It preferably has a tensile modulus (according to ISO R527) of greater than 2.5, preferably greater than 3, especially greater than 3.5 GPa. The tensile modulus may be less than 40, suitably less than 30, preferably less than 20, more preferably less than 10 GPa.
- flexural strength (according to ASTM D695) of at least 100, more preferably at least 110, especially at least 115 MPa.
- the flexural strength may be less than 650, preferably less than 400, more preferably less than 260, especially less than 200 MPa.
- the flexural modulus may be less than 60, suitably less than 25, preferably less than
- a continuous carbon fibre polyetheretherketone may typically have a tensile strength of about 350 MPa, a tensile modulus of 36 GPa, an elongation of 2%, a flexural modulus of 50 GPa and a flexural strength of 620 MPa.
- a said porous layer may be provided on any part of said medical device or part thereof which may come into contact with body fluids in use.
- the method of the first aspect may include a first method type which includes treating a region on the outside of said support material to render it porous.
- the region which is treated may be a part of said support material (in which case it suitably includes a polymer having moieties I, II and/or III described herein) or may comprise a layer of a polymer having moieties I, II and/or III which is applied to the support material (which preferably comprises a polymer having moieties I, II and/or III) prior to the treatment.
- said layer which is to be rendered porous is preferably part of or associated with said support material prior to said layer being rendered porous.
- said layer which is to be rendered porous comprises a polymer having moieties I, II and/or III, wherein phenyl moieties in moieties I, II and/or III are not optionally-substituted or optionally cross-linked.
- Said layer which is to be rendered porous optionally includes an X-ray contrast medium as described therein.
- said support material is arranged in a shape which represents or is a precursor of a medical device or part thereof.
- a said layer of polymer may be applied to said support material.
- said support material having at least a layer of a said polymer having moieties I, II and/or III is placed in an environment which is at a temperature of at least 20 °C above the glass transition temperature of the polymer and at least 30°C below the melting temperature of the polymer.
- the environment is suitably pressurised, suitably at 20-50 MPa, with a supercritical fluid, especially carbon dioxide. Consequently, the fluid diffuses into the polymer.
- the fluid pressure may be released and preferably the temperature in the environment is reduced, suitably relatively rapidly, below the glass transition temperature of the polymer.
- the layer on the outside of the support material is thereafter found to be porous .
- the properties and/or arrangement of the porous layer formed can be varied to suit any particular application and/or desired characteristics .
- the polymer rendered porous may not be functionalised in the method and, accordingly, the polymer prior to and subsequent to the treatment is chemically unchanged.
- a useful porous layer may be formed using supercritical carbon dioxide at 260 °C and 34.5 MPa (5- 7 00 ⁇ — s-ig-)- for——5—ous. - - ⁇
- a surface of said support material having at least a layer of said polymer having moieties I, II and/or III is contacted with a solvent in order to dissolve polymer at said surface.
- said support material may be immersed in the solvent.
- the polymer is caused to precipitate at the surface by diluting the solvent, for example by contacting said surface with a solvent which is not capable of solvating the polymer.
- the depth of the porous layer and/or pore sizes are dependent upon the nature of the solvent, the solvent concentration, the temperature and the time of contact of said solvent with said support material .
- suitable solvents that may be used to dissolve include sulphuric acid, methanesulphonic acid and phenol/dichlorobenzene .
- solvents may, in addition to solvating the polymer, chemically react with it to functionalise it.
- Sulphonating solvents for example sulphuric acid such as 98% sulphuric acid, may sulphonate polymers of the type described.
- said solvent may sulphonate phenyl moieties in -0-(Ph) n -0- moieties in said polymer where Ph represents a phenyl moiety and n represents an integer (preferably 1) .
- a porous functionalised (e.g. sulphonated) layer may be produced in the method.
- the polymer rendered porous may be chemically changed during the treatment, for example by functionalisation of phenyl moieties as described.
- The- metho -o the- -f-ir-st—-aspect— ay- include a second method type wherein a layer of material which is arranged to be porous (hereinafter "precursor material") is applied to the support material, wherein said precursor material includes a polymer having moieties I, II and/or III as described herein.
- Said precursor material suitably includes at least 30wt%, preferably at least 40wt%, more preferably at least 50wt%, especially at least 60wt% of a said polymer having moieties I, II and/or III.
- Said precursor material may include an X-ray contrast medium as described. Any desired depth of said precursor material may be applied to the support according to the desired depth of the porous layer.
- said precursor material is applied as a porous material .
- a foamed material may be applied to the support material.
- Supercritical carbon dioxide may be used as described with reference to said first embodiment of said first method.
- said polymer having moieties I, II and/or III and any other components which are to make up the precursor material may be heated in an environment at a temperature of at least 20 °C above the glass transition temperature of the polymer used and at least 30 °C below the melting temperature of the polymer.
- the environment is suitably pressurised with a supercritical fluid, especially carbon dioxide so that the fluid diffuses into the polymer.
- the molten mixture may be extruded into an atmosphere of lower pressure, whereupon as the pressure on the melt reduces upon exiting an extrusion orifice, a foam is formed.
- This foam may be injection moulded on to the support material or, alternatively, the molten mixture and the support material may be co-extruded so that the foam is di-recfc-1y---t-ransferred--t-o —the—support --material as it exits an extruder.
- said polymer of said precursor material is not chemically changed, for example functionalised in the method and, accordingly, said polymer before and after contact with said support material is chemically unchanged.
- said precursor material is arranged to be rendered porous, suitably after it has been contacted with the support material.
- said precursor material comprises a material (hereinafter a "removable material") which can be removed, for example dissolved out of said precursor material, when said precursor material is present on the support material, whereby a porous structure is produced by virtue of the voids defined in regions from which said removable material has been removed.
- the method preferably includes contacting the precursor ' material, when it is present on said support material, with solvent which solubilises the removable material but not the polymer having moieties I, II and/or III.
- the polymer is semi-crystalline so as to render it less soluble in solvents that may be used to solubilise the removable material.
- said polymer of said precursor material is not functionalised in the method, so said polymer before and after contact with said solvent is preferably chemically unchanged.
- said removable material may comprise an amorphous high temperature polymer or polymers which is/are preferably blended with said polymer having moieties I, II and/or III, wherein each amorphous polymer used is incompatible with said polymer having moieties I, II and/or III.
- Blending is preferably by a melt process, suitably using a twin screw extruder. The total amount of said amorphous polymer in the blend may be less than 40%wt.
- An X-ray contrast medium may be included in the blend as described herein.
- the blend may be contacted with the support material for example by being injection moulded or extruded directly onto the support material.
- the morphology is that of a continuous matrix of the larger volume component (e.g, the polymer having moieties I, II and/or III) with domains of the lower volume component
- the method may then involve immersing the composite comprising support material and precursor material in a solvent which will dissolve out the removable material leaving a microporous structure of the polymer having moieties I, II and/or III that is firmly attached to the support.
- the solvent may be selected to effect dissolution according to the identity of the removable material .
- the identity and/or physical form of the amorphous polymer affects the nature of the porous layer produced in the method. Whilst polysulphone or polyethersulphones may be used, there is a tendency for the resultant pores produced to -be- -too- -small- for bone -ingrowth. It is preferred that polymers are selected which, when removed, yield pores, preferably a majority thereof, in the range 50-500 ⁇ m. Suitable polymers may be less compatible with said polymer having moieties I, II and/or III (especially the preferred examples thereof described herein) than polyethersulphone or polysulphone is with said polymer. Said removable material is preferably a polymer which does not include ether groups in its polymer chain.
- said removable material has a polymer backbone of the same type as described for said polymer having moieties I, II and/or III, there are preferably bulky groups pendent from the backbone to render it incompatible with said polymer having moieties I, II and/or III. It is especially preferred for said removable material not to be a polyketone or polysulphone polymer. Examples of preferred polymers are high temperature nylons, high temperature silane polymers and polymers that incorporate fluorine atoms .
- said removable material may comprise a fugitive compound which is preferably blended with said polymer having moieties I, II and/or III.
- Said fugitive compound is preferably thermally stable at 400 °C and preferably includes particles, preferably a majority t ereof, in the range 50-500 ⁇ m. At least 5wt%, preferably at least 20wt%, more preferably at least 15wt% of said fugitive compound may be present in the precursor material .
- the amount of said compound in said precursor material is preferably less than 60wt%, more preferably less than 50wt%, especially 40wt% or less.
- Said precursor material may include an X-ray contrast medium, as described, for -example in- the- range- -3- ⁇ 2-5wt% ⁇
- Preferred fugitive compounds are inorganic, especially inorganic salts.
- the polymer having moieties I, II and/or III is filled with said fugitive compound and said X-ray contrast medium, if provided, using a melt processing technique.
- the blend may be contacted with the support material for example by being injection moulded or extruded directly onto the support material. After solidification, the composite of support material and precursor material is immersed in a solvent to remove the fugitive compound and yield a microporous three- dimensional surface.
- the solvent used is preferably an acid, for example hydrochloric acid.
- the acid used has a negligible effect on the polymer having moieties I, II and/or III itself.
- a porous material may be prepared as described in applicant's co-pending application no GB 0101098.2.
- the method described therein may be used to prepare a porous (foamed) layer on the outside of a support material .
- the layer may be formed by heating a mixture which includes a said polymer having moieties I, II and/or III and a decomposable material comprising a magnesium moiety and a hydroxide moiety (e.g. magnesium hydroxide) to a foaming temperature at or above the decomposition temperature of the decomposable material .
- the porous layer may be extruded onto the support material .
- -the method may include a further treatment of a porous layer after it has been formed, for example to reveal elements of the microporous structure that would otherwise not be exposed to body fluids, in use. Further treatment may involve machining the porous layer after it has been prepared. Furthermore, in some embodiments, the method may involve removing the porous layer in its entirety, for example in regions of the medical device or part thereof that do not contact body fluids in use or otherwise are not required to be adapted for bone ingrowth in osseo-integration.
- the method of the first aspect may include associating bio-compatible moieties with said polymer which includes moieties I, II and/or III of said porous layer.
- the method preferably includes the step of treating said polymer with a material for providing bio-compatible moieties (hereinafter "BCM material").
- BCM material may be arranged to provide any of the bio-compatible moieties described hereinafter.
- Said polymer may be provided as a solid.
- said bio-compatible moieties are caused to become associated with a surface of said porous layer of said solid.
- Said solid is preferably shaped so as to represent at least a part of a device for use in medical applications, as described above.
- bio-compatible material formed is not engineered or otherwise treated in a manner which may result in substantial depletion of the bio-compatible moieties associated with its surface.
- bio-compatible has generally been used to refer to a material which is compatible with use in medical applications, for example by not being toxic or otherwise harmful to living materials . It also encompasses materials which have a biological or physiological effect when associated with living materials.
- said bio-compatible polymeric material has improved or enhanced bio-compatibility compared to said polymer having moieties I, II and/or III in said porous layer, in the absence of associated bio-compatible moieties .
- Bio-compatible moieties suitably include moieties arranged to reduce adverse biological reactions when the bio-compatible polymeric material is introduced into (or otherwise associated with) a human or animal body.
- adverse biological reactions associated with introduction into a human or animal body of said polymer having said bio-compatible moieties may be less compared to use of the same polymer but which does not include associated bio-compatible moieties.
- Bio-compatible moieties referred to herein suitably refer to moieties which are compatible with use in medical applications, for example by not being toxic or otherwise harmful to living material. Such bio-compatible moieties may be arranged to bond (for example to form ionic or covalent bonds) or otherwise interact with materials present in human or animal ⁇ bodies "in “ “order ⁇ t ⁇ “Improve their integration and acceptance by such bodies.
- a said bio-compatible moiety may be selected from an ⁇ anticoagulant agent such as heparin and heparin sulfate, an antithrombotic agent, a clotting agent, a platelet agent, an anti-inflammatory agent, an antibody, an antigen, an immunoglobulin, a defence agent, an enzyme, a hormone, a growth factor, a neurotransmitter, a cytokine, a blood agent, a regulatory agent, a transport agent, a fibrous agent, a protein such as avidin, a glycoprotein, a globular protein, a structural protein, a membrane protein and a cell attachment protein, a peptide such as a glycopeptide, a structural peptide, a membrane peptide and a cell attachment peptide, a proteoglycan, a toxin, ' an antibiotic agent, an antibacterial agent, an antimicrobial agent such as pencillin, ticarcillin, carbenicillin, ampicillin, oxacillian, ce
- poly (ethylene glycol) (PEG) poly (ethylene oxide) (PEO) , ethylene oxide- propylene oxide block co-polymers, poly (N-vinyl-2- pyrrolidone) (P VP) , poly (2-hydroxyethyl methacrylate)
- HEMA HEMA co-polymers
- PVA poly (vinyl alcohol)
- PVA polyacrylamide
- PMMA polyacrylamide
- PMMA suitably having a PEG chain on each of the side groups, polysiloxanes (e.g. polydimethylsiloxanes (PDMS) ) , ionic water-soluble polymers like poly (acrylic acid) (PAAc) ) and a polyurethane .
- PDMS polydimethylsiloxanes
- PAAc polyacrylic acid
- said bio-compatible moieties may comprise bone morphogenic protein (BMP) as described in US4563489 and patents cited therein and the contents of the aforesaid are incorporated herein.
- BMP bone morphogenic protein
- Said BMP may be provided in combination, for example in admixture, with a physiologically acceptable biodegradable organic polymer and said biodegradable polymer may be associated with said at least two moieties of said polymer of said bio- compatible polymeric material, for example by being covalently bonded to said at least two moieties.
- the combination of said biodegradable polymer and BMP defines said bio-compatible moieties.
- Said biodegradable polymer is preferably a biodegradable polylactic acid; or alternatively, other physiologically acceptable biodegradable organic polymers which are structurally equivalent to polylactic acid can be used as the delivery system for BMP.
- examples include poly(hydroxy organic carboxylic acids) e.g. poly(hydroxy aliphatic carboxylic acids) , polyglycollic acid, polyglactin, polyglactic acid and poly adonic acids.
- said bio-compatible moieties may be selected from inorganic crystalline structures, inorganic -amorphous - structures, organic crystalline structures and organic amorphous structures .
- Preferred bio-compatible moieties are phosphorous based ceramics, for example calcium-phosphorous ceramics .
- Phosphates in general are suitable but calcium phosphates and calcium apatite are preferred.
- bio-compatible moieties may be associated by any suitable means with the porous layer, for example by covalent bond(s) , hydrogen bond(s) , encapsulation in a matrix which is bonded to or otherwise interacts with said layer or by ionic interaction (s) , it is preferred that there are covalent bonds between the bio-compatible moieties and said polymer having moieties I, II and/or III in said porous layer or there are ionic interactions between said bio-compatible moieties and said polymer.
- the method may include functionalising said porous layer after its formation thereby to enable association with said bio-compatible moieties.
- said polymer which includes moieties I, II and/or III may be functionalised prior to or during formation of said porous layer.
- An example of the latter is Example 2 hereinafter wherein the polymer is sulphonated during formation of said porous layer.
- the porous layer may be treated with a diisocyanate and a diol thereby to associate a polyurethane with said porous layer.
- the porous layer may be treated with a diisocyanate and a diol thereby to associate a polyurethane with said porous layer .
- said support material is preferably formed into a shape which represents or is a precursor of a medical device or part thereof . Formation into a shape may use any suitable method, for example, moulding, machining of a blank, extrusion or the like. Then, said porous layer is formed on the outside of the support material in desired regions thereof using a method described herein. The porous layer may be further treated for example to functionalise it and/or to associate bio-compatible moieties with it.
- the method may be used for making any type of medical device or part thereof (as described in the introduction of this specification)
- the medical device or part thereof is preferably for an orthopaedic implant, especially for a body joint, for example a hip or knee joint or spine fusion device.
- the invention extends to a method of making a medical device or part thereof, the method comprising: forming a material into a shape which represents or is a precursor of a device for use in medical applications wherein said material comprises a polymer; and treating material in said shape in order to define a porous layer on the outside of said shape, wherein said porous layer comprises a polymer having moieties I, II and/or III as described herein.
- a medical device or part thereof which includes a support material and a porous layer on the
- porous layer includes a polymer having a moiety of formula I and/or of formula II and/or of formula III as described according to the first aspect wherein said polymer is optionally associated with bio-compatible moieties.
- said support material also comprises a polymer having a moiety of formula I and/or II and/or III.
- said polymer in the support material and said polymer in said porous layer have the same polymeric backbone. They may differ in terms of whether phenyl moieties are functionalised and/or since bio-compatible moieties may be associated with said porous layer.
- the polymer is polyetheretherketone or polyetherketone or a functionalised derivative thereof
- a polymer having a moiety of formula I and/or II and/or III may be prepared as described in PCT/GB99/02833.
- the invention extends to a method of making a medical device or part thereof, the method including the step of forming a layer (hereinafter an "X-ray contrast layer”) on the outside of a support material, wherein said layer includes an X-ray contrast medium.
- a layer hereinafter an "X-ray contrast layer”
- Said X-ray contrast layer may have any feature of the porous layer described herein.
- Said support material may have any feature of a said support material described in any statement herein.
- said support material includes a lower amount of X-ray contrast medium than said X-ray contrast layer.
- said support material includes substantially no X-ray contrast medium.
- PEEK Trade Mark
- PEK Trade Mark
- Hydrofy GS 1.5 (Trade Mark) a mineral containing >90% magnesium hydroxide obtained from Nuova Sima Sri of Genga,
- the plaque had a porous surface of sulphonated PEEKTM with predominantly 50 - 400 ⁇ m pores.
- Example 3 Formation of a porous surface on polyaryleth ⁇ retherketone using calcium carbonate.
- Polyaryletheretherketone 450G (Victrex pic) was mixed with nominally 250 ⁇ m particulate calcium carbonate at 40% by weight using a 25 mm single screw extruder. The resultant mixture was injection moulded into 3.2 mm thick plaques (150 x 150 mm) . The plaques were transferred to a bath of 2M Hydrochloric acid. After a soak time of 2 hours the resultant plaque had a three dimensional microporous surface. The pores were measured in the range 60 to 300 ⁇ m.
- the size of the resulting particles in the polymer were reduced from nominally 250 ⁇ m to a range that yielded predominantly 60-300 ⁇ m pores.
- 450G polyaryletheretherketone supplied by Victrex pic was mixed with nominally 100 micron barium sulphate powder (Merck, UK) in a Marion Tumble blender for 30 minutes. The resultant mixture was fed into a 32 mm single screw extruder. The mixture was extruded and cooled as a lace in air, prior to granulation. The mixed pellets were placed in trays (approximately 2.5 cm deep) in an air circulating oven at 130 °C for 5 hours. The pellets were then injection molded using a Neggri Bossi 100 tones clamping force moulder to form 150 mm x 150 mm x 6 mm plaques .
- Plaques were then placed in a cavity 5 mm larger than the plaque depth and 10 mm wider than the plaque width and length.
- the cavity was placed in 200 tpsi heated platen press, fitted with thermocouples and a water cooling system.
- the nominal temperature of the platens was set to 280 C and the clamping force was increased to a maximum value.
- the temperature was allowed to stabilize prior to the cavity being pressurised with supercritical carbon dioxide at 40 MPa. The pressure and temperature was maintained for 5 hours .
- the sample was removed from the tool when the thermocouple readings fell below 80 C.
- the plaque had the surface finish machined off (approximately 0.25 mm) to reveal a complex microstructure of pores .
- the pores were predominately in the size range 50 to 500 microns and discrete.
- High viscosity polyaryletheretherketone (450G) has been used in a series of experiments to produce foamed components of densities varying in the range 0.35 to 0.90 g cm "3 .
- the supercritical fluid used was C0 2 and was introduced to the melt after compaction via a poppet valve. After the introduction of the supercritical fluid the temperatures used to process the melt were reduced from 400 to 300 °C.
- the extrudate was expelled through an adjustable slit die as a foam on to a strip of PEEK film cut to fit onto a laboratory sized band caster. As the bandcaster rotated the extruded material formed a drawn foamed layer on the surface of the PEEK film.
- A- sect-ion- of- this- foamed composite strip was removed, mounted on a solid plaque and the foamed surface subjected to mechanical abrassion so as to revove the surface layer.
- the exposed surface structure was seen under an optical microscope as comprising a complex microstructure of pores. The pores were predominantly in the size range 50 to 200 microns.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Dispersion Chemistry (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU74322/01A AU7432201A (en) | 2000-06-24 | 2001-06-22 | Bio-compatible polymeric materials |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0015430.2 | 2000-06-24 | ||
GB0015430A GB0015430D0 (en) | 2000-06-24 | 2000-06-24 | Bio-compatible polymeric materials |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002000275A1 true WO2002000275A1 (en) | 2002-01-03 |
Family
ID=9894274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/002786 WO2002000275A1 (en) | 2000-06-24 | 2001-06-22 | Bio-compatible polymeric materials |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU7432201A (en) |
GB (1) | GB0015430D0 (en) |
WO (1) | WO2002000275A1 (en) |
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003077965A1 (en) * | 2002-03-13 | 2003-09-25 | University Of Nottingham | Polymer composition loaded with cells |
WO2004006973A1 (en) * | 2002-07-06 | 2004-01-22 | Kensey Nash Corporation | Resorbable structure for treating and healing of tissue defects |
EP1454946A1 (en) * | 2003-02-24 | 2004-09-08 | Basf Aktiengesellschaft | Open celled foam of high melting point polymer |
EP1468703A1 (en) | 2003-04-15 | 2004-10-20 | Depuy Products, Inc. | Implantable orthopaedic device |
US7087084B2 (en) | 1999-10-22 | 2006-08-08 | Archus Orthopedics, Inc. | Method for replacing a natural facet joint with a prosthesis having an artificial facet joint structure |
US7290347B2 (en) | 2004-04-22 | 2007-11-06 | Archus Orthopedics, Inc. | Facet joint prosthesis measurement and implant tools |
US7406775B2 (en) | 2004-04-22 | 2008-08-05 | Archus Orthopedics, Inc. | Implantable orthopedic device component selection instrument and methods |
US7549984B2 (en) | 2004-06-16 | 2009-06-23 | Pneumrx, Inc. | Method of compressing a portion of a lung |
US7608104B2 (en) | 2003-05-14 | 2009-10-27 | Archus Orthopedics, Inc. | Prostheses, tools and methods for replacement of natural facet joints with artifical facet joint surfaces |
US7670282B2 (en) | 2004-06-14 | 2010-03-02 | Pneumrx, Inc. | Lung access device |
US7674293B2 (en) | 2004-04-22 | 2010-03-09 | Facet Solutions, Inc. | Crossbar spinal prosthesis having a modular design and related implantation methods |
WO2010030993A1 (en) | 2008-09-12 | 2010-03-18 | Pneumrx, Inc. | Improved and/or longer minimally invasive lung volume reduction devices and their delivery |
US7691145B2 (en) | 1999-10-22 | 2010-04-06 | Facet Solutions, Inc. | Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces |
US7766891B2 (en) | 2004-07-08 | 2010-08-03 | Pneumrx, Inc. | Lung device with sealing features |
US7766938B2 (en) | 2004-07-08 | 2010-08-03 | Pneumrx, Inc. | Pleural effusion treatment device, method and material |
WO2010135352A1 (en) | 2009-05-18 | 2010-11-25 | Pneumrx, Inc. | Cross-sectional modification during deployment of an elongate lung volume reduction device |
US7846162B2 (en) | 2005-05-18 | 2010-12-07 | Sonoma Orthopedic Products, Inc. | Minimally invasive actuable bone fixation devices |
EP2292188A2 (en) | 2002-11-27 | 2011-03-09 | Conformis, Inc. | Patient selectable surgical tools |
US7909825B2 (en) | 2006-11-22 | 2011-03-22 | Sonoma Orthepedic Products, Inc. | Fracture fixation device, tools and methods |
US7914556B2 (en) | 2005-03-02 | 2011-03-29 | Gmedelaware 2 Llc | Arthroplasty revision system and method |
EP2324799A2 (en) | 2004-11-24 | 2011-05-25 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
EP2335654A1 (en) | 2003-11-25 | 2011-06-22 | Conformis, Inc. | Patient selectable knee joint arthoplasty devices |
USRE43282E1 (en) | 1998-09-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
US8157837B2 (en) | 2006-03-13 | 2012-04-17 | Pneumrx, Inc. | Minimally invasive lung volume reduction device and method |
US8187303B2 (en) | 2004-04-22 | 2012-05-29 | Gmedelaware 2 Llc | Anti-rotation fixation element for spinal prostheses |
US8221461B2 (en) | 2004-10-25 | 2012-07-17 | Gmedelaware 2 Llc | Crossbar spinal prosthesis having a modular design and systems for treating spinal pathologies |
US8231655B2 (en) | 2003-07-08 | 2012-07-31 | Gmedelaware 2 Llc | Prostheses and methods for replacement of natural facet joints with artificial facet joint surfaces |
US8287539B2 (en) | 2005-05-18 | 2012-10-16 | Sonoma Orthopedic Products, Inc. | Fracture fixation device, tools and methods |
EP2520255A1 (en) | 2005-11-21 | 2012-11-07 | Vertegen, Inc. | Devices and methods for treating facet joints, uncovertebral joints, costovertebral joints and other joints |
US8398681B2 (en) | 2004-08-18 | 2013-03-19 | Gmedelaware 2 Llc | Adjacent level facet arthroplasty devices, spine stabilization systems, and methods |
US8409254B2 (en) | 2003-05-14 | 2013-04-02 | Gmedelaware 2 Llc | Prostheses, tools and methods for replacement of natural facet joints with artificial facet joint surfaces |
US8496686B2 (en) | 2005-03-22 | 2013-07-30 | Gmedelaware 2 Llc | Minimally invasive spine restoration systems, devices, methods and kits |
WO2013131066A1 (en) | 2012-03-02 | 2013-09-06 | Conformis, Inc. | Patient-adapted posterior stabilized knee implants, designs and related methods and tools |
EP2649951A2 (en) | 2006-02-06 | 2013-10-16 | ConforMIS, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US8702755B2 (en) | 2006-08-11 | 2014-04-22 | Gmedelaware 2 Llc | Angled washer polyaxial connection for dynamic spine prosthesis |
EP2754419A2 (en) | 2011-02-15 | 2014-07-16 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs and related tools |
WO2014151557A2 (en) | 2013-03-15 | 2014-09-25 | Pneumrx, Inc. | Torque alleviating intra-airway lung volume reduction compressive implant structures |
US8862202B2 (en) | 1998-09-14 | 2014-10-14 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and preventing damage |
US8888800B2 (en) | 2006-03-13 | 2014-11-18 | Pneumrx, Inc. | Lung volume reduction devices, methods, and systems |
US8951260B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Surgical cutting guide |
US8961516B2 (en) | 2005-05-18 | 2015-02-24 | Sonoma Orthopedic Products, Inc. | Straight intramedullary fracture fixation devices and methods |
US9017334B2 (en) | 2009-02-24 | 2015-04-28 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US9023050B2 (en) | 2001-05-25 | 2015-05-05 | Conformis, Inc. | Surgical tools for arthroplasty |
US9056016B2 (en) | 2003-12-15 | 2015-06-16 | Gmedelaware 2 Llc | Polyaxial adjustment of facet joint prostheses |
US9055953B2 (en) | 2001-05-25 | 2015-06-16 | Conformis, Inc. | Methods and compositions for articular repair |
US9060820B2 (en) | 2005-05-18 | 2015-06-23 | Sonoma Orthopedic Products, Inc. | Segmented intramedullary fracture fixation devices and methods |
US9066728B2 (en) | 2001-05-25 | 2015-06-30 | Conformis, Inc. | Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty |
US9125639B2 (en) | 2004-11-23 | 2015-09-08 | Pneumrx, Inc. | Steerable device for accessing a target site and methods |
US9155574B2 (en) | 2006-05-17 | 2015-10-13 | Sonoma Orthopedic Products, Inc. | Bone fixation device, tools and methods |
US9286686B2 (en) | 1998-09-14 | 2016-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and assessing cartilage loss |
WO2016046715A1 (en) * | 2014-09-25 | 2016-03-31 | Università Degli Studi Di Trento | Method for manufacturing porous scaffolds for biomedical uses and scaffolds thereof |
US9308053B2 (en) | 2006-02-06 | 2016-04-12 | Conformis, Inc. | Patient-specific joint arthroplasty devices for ligament repair |
US9326780B2 (en) | 2006-02-06 | 2016-05-03 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief |
US9402633B2 (en) | 2006-03-13 | 2016-08-02 | Pneumrx, Inc. | Torque alleviating intra-airway lung volume reduction compressive implant structures |
WO2016134409A1 (en) * | 2015-02-27 | 2016-09-01 | The University Of Sydney | Biomedical implantable materials |
US9486226B2 (en) | 2012-04-18 | 2016-11-08 | Conformis, Inc. | Tibial guides, tools, and techniques for resecting the tibial plateau |
US9486558B2 (en) | 2003-03-27 | 2016-11-08 | Locate Therapeutics Limited | Porous matrix |
US9579110B2 (en) | 2001-05-25 | 2017-02-28 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9642632B2 (en) | 2009-02-24 | 2017-05-09 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
US9649117B2 (en) | 2009-02-24 | 2017-05-16 | Microport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US9675471B2 (en) | 2012-06-11 | 2017-06-13 | Conformis, Inc. | Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components |
EP3187153A2 (en) | 2005-09-30 | 2017-07-05 | Conformis, Inc. | Bearing implant |
US9770278B2 (en) | 2014-01-17 | 2017-09-26 | Arthrex, Inc. | Dual tip guide wire |
US9801637B2 (en) | 2006-03-13 | 2017-10-31 | Pneumrx, Inc. | Genetically-associated chronic obstructive pulmonary disease treatment |
US9814499B2 (en) | 2014-09-30 | 2017-11-14 | Arthrex, Inc. | Intramedullary fracture fixation devices and methods |
US9931438B2 (en) * | 2008-01-28 | 2018-04-03 | Ngk Spark Plug Co., Ltd. | Article with foamed surface, implant and method of producing the same |
US10390838B1 (en) | 2014-08-20 | 2019-08-27 | Pneumrx, Inc. | Tuned strength chronic obstructive pulmonary disease treatment |
US10537334B2 (en) | 2013-10-25 | 2020-01-21 | Pneumrx, Inc. | Genetically-associated chronic obstructive pulmonary disease treatment |
CN111184913A (en) * | 2020-01-13 | 2020-05-22 | 吉林大学 | Artificial bone composite material based on polyether-ether-ketone and preparation method thereof |
CN111939319A (en) * | 2019-05-17 | 2020-11-17 | 北京化工大学 | A kind of bioactive porous polyetheretherketone and its preparation method and application |
CN112972764A (en) * | 2021-03-19 | 2021-06-18 | 吉林大学 | Polyether-ether-ketone bone repair material with multi-scale holes and preparation method thereof |
CN113398328A (en) * | 2021-05-12 | 2021-09-17 | 上海云合景从新材料科技有限公司 | Porous polyether-ether-ketone and preparation method and application thereof |
EP3746139B1 (en) | 2018-02-02 | 2023-07-05 | Evonik Operations GmbH | Functionally graded polymer knee implant for enhanced fixation, wear resistance, and mechanical properties and the fabrication thereof |
US12108959B2 (en) | 2019-05-29 | 2024-10-08 | Wright Medical Technology, Inc. | Preparing a tibia for receiving tibial implant component of a replacement ankle |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0269256A1 (en) * | 1986-11-04 | 1988-06-01 | Pfizer Hospital Products Group, Inc. | Method of forming tissue ingrowth surface on surgical implants |
EP0283187A2 (en) * | 1987-03-17 | 1988-09-21 | Imperial Chemical Industries Plc | Films and tapes |
US4859715A (en) * | 1984-05-18 | 1989-08-22 | Raychem Corporation | Microporous poly (arylether ketone) article |
WO1991009079A1 (en) * | 1989-12-14 | 1991-06-27 | Farmitalia Carlo Erba S.R.L. | Use of supercritical fluids to obtain porous sponges of biodegradable polymers |
EP0610953A1 (en) * | 1993-02-11 | 1994-08-17 | Minnesota Mining And Manufacturing Company | Thermoplastic foamed articles and a method of making thereof |
EP0659389A1 (en) * | 1993-10-20 | 1995-06-28 | Schneider (Europe) Ag | Endoprothese |
US5969020A (en) * | 1993-08-13 | 1999-10-19 | Poly-Med, Inc. | Microporous polymeric foams and microtextured surfaces |
EP1099468A2 (en) * | 1999-11-10 | 2001-05-16 | DEUTSCHE INSTITUTE FÜR TEXTIL- UND FASERFORSCHUNG STUTTGART Stiftung des öffentlichen Rechts | Microporous hydrophilic membrane |
-
2000
- 2000-06-24 GB GB0015430A patent/GB0015430D0/en not_active Ceased
-
2001
- 2001-06-22 AU AU74322/01A patent/AU7432201A/en not_active Abandoned
- 2001-06-22 WO PCT/GB2001/002786 patent/WO2002000275A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859715A (en) * | 1984-05-18 | 1989-08-22 | Raychem Corporation | Microporous poly (arylether ketone) article |
EP0269256A1 (en) * | 1986-11-04 | 1988-06-01 | Pfizer Hospital Products Group, Inc. | Method of forming tissue ingrowth surface on surgical implants |
EP0283187A2 (en) * | 1987-03-17 | 1988-09-21 | Imperial Chemical Industries Plc | Films and tapes |
WO1991009079A1 (en) * | 1989-12-14 | 1991-06-27 | Farmitalia Carlo Erba S.R.L. | Use of supercritical fluids to obtain porous sponges of biodegradable polymers |
EP0610953A1 (en) * | 1993-02-11 | 1994-08-17 | Minnesota Mining And Manufacturing Company | Thermoplastic foamed articles and a method of making thereof |
US5969020A (en) * | 1993-08-13 | 1999-10-19 | Poly-Med, Inc. | Microporous polymeric foams and microtextured surfaces |
EP0659389A1 (en) * | 1993-10-20 | 1995-06-28 | Schneider (Europe) Ag | Endoprothese |
EP1099468A2 (en) * | 1999-11-10 | 2001-05-16 | DEUTSCHE INSTITUTE FÜR TEXTIL- UND FASERFORSCHUNG STUTTGART Stiftung des öffentlichen Rechts | Microporous hydrophilic membrane |
Non-Patent Citations (1)
Title |
---|
RENARDY M ET AL: "MEMBRANES FOR A BIOHYBRID PANCREAS", ADVANCES IN BIOMATERIALS, 1990, pages 633 - 638, XP001034375, ISSN: 0272-3840 * |
Cited By (161)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8862202B2 (en) | 1998-09-14 | 2014-10-14 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and preventing damage |
USRE43282E1 (en) | 1998-09-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
US9286686B2 (en) | 1998-09-14 | 2016-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and assessing cartilage loss |
US7608106B2 (en) | 1999-10-22 | 2009-10-27 | Archus Orthopedics, Inc. | Facet arthroplasty devices and methods |
US8092532B2 (en) | 1999-10-22 | 2012-01-10 | Gmedelaware 2 Llc | Facet arthroplasty devices and methods |
US8070811B2 (en) | 1999-10-22 | 2011-12-06 | Gmedelaware 2 Llc | Facet arthroplasty devices and methods |
US8066740B2 (en) | 1999-10-22 | 2011-11-29 | Gmedelaware 2 Llc | Facet joint prostheses |
US7087084B2 (en) | 1999-10-22 | 2006-08-08 | Archus Orthopedics, Inc. | Method for replacing a natural facet joint with a prosthesis having an artificial facet joint structure |
US7691145B2 (en) | 1999-10-22 | 2010-04-06 | Facet Solutions, Inc. | Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces |
US9125672B2 (en) | 2001-05-25 | 2015-09-08 | Conformis, Inc. | Joint arthroplasty devices and surgical tools |
US9216025B2 (en) | 2001-05-25 | 2015-12-22 | Conformis, Inc. | Joint arthroplasty devices and surgical tools |
US9066728B2 (en) | 2001-05-25 | 2015-06-30 | Conformis, Inc. | Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty |
US8951259B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US8951260B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Surgical cutting guide |
US9358018B2 (en) | 2001-05-25 | 2016-06-07 | Conformis, Inc. | Joint arthroplasty devices and surgical tools |
US9295482B2 (en) | 2001-05-25 | 2016-03-29 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9579110B2 (en) | 2001-05-25 | 2017-02-28 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US8998915B2 (en) | 2001-05-25 | 2015-04-07 | Conformis, Inc. | Joint arthroplasty devices and surgical tools |
US9023050B2 (en) | 2001-05-25 | 2015-05-05 | Conformis, Inc. | Surgical tools for arthroplasty |
US9084617B2 (en) | 2001-05-25 | 2015-07-21 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9072531B2 (en) | 2001-05-25 | 2015-07-07 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9055953B2 (en) | 2001-05-25 | 2015-06-16 | Conformis, Inc. | Methods and compositions for articular repair |
US9186161B2 (en) | 2001-05-25 | 2015-11-17 | Conformis, Inc. | Surgical tools for arthroplasty |
US9125673B2 (en) | 2001-05-25 | 2015-09-08 | Conformis, Inc. | Joint arthroplasty devices and surgical tools |
US9107679B2 (en) | 2001-05-25 | 2015-08-18 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9107680B2 (en) | 2001-05-25 | 2015-08-18 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
WO2003077965A1 (en) * | 2002-03-13 | 2003-09-25 | University Of Nottingham | Polymer composition loaded with cells |
US7049348B2 (en) | 2002-07-06 | 2006-05-23 | Kensey Nash Corporation | Resorbable structure for treating and healing of tissue defects |
WO2004006973A1 (en) * | 2002-07-06 | 2004-01-22 | Kensey Nash Corporation | Resorbable structure for treating and healing of tissue defects |
EP2292189A2 (en) | 2002-11-27 | 2011-03-09 | Conformis, Inc. | Patient selectable surgical tools |
EP2292188A2 (en) | 2002-11-27 | 2011-03-09 | Conformis, Inc. | Patient selectable surgical tools |
EP1454946A1 (en) * | 2003-02-24 | 2004-09-08 | Basf Aktiengesellschaft | Open celled foam of high melting point polymer |
US7655705B2 (en) | 2003-02-24 | 2010-02-02 | Basf Aktiengesellschaft | Open-cell foam composed of high-melting point plastics |
US10232087B2 (en) | 2003-03-27 | 2019-03-19 | Locate Therapeutics Limited | Porous matrix |
US9486558B2 (en) | 2003-03-27 | 2016-11-08 | Locate Therapeutics Limited | Porous matrix |
EP1468703A1 (en) | 2003-04-15 | 2004-10-20 | Depuy Products, Inc. | Implantable orthopaedic device |
US7938861B2 (en) | 2003-04-15 | 2011-05-10 | Depuy Products, Inc. | Implantable orthopaedic device and method for making the same |
AU2004201549B2 (en) * | 2003-04-15 | 2009-08-13 | Depuy Products, Inc. | Implantable orthopaedic device and method for making the same |
EP2191852A3 (en) * | 2003-04-15 | 2010-07-21 | DePuy Products, Inc. | Implantable orthopaedic device |
EP2191852A2 (en) | 2003-04-15 | 2010-06-02 | DePuy Products, Inc. | Implantable orthopaedic device |
JP2004313794A (en) * | 2003-04-15 | 2004-11-11 | Depuy Products Inc | Production method of implantable orthopedic device and orthopedic device |
US9198766B2 (en) | 2003-05-14 | 2015-12-01 | Gmedelaware 2 Llc | Prostheses, tools, and methods for replacement of natural facet joints with artificial facet joint surfaces |
US7608104B2 (en) | 2003-05-14 | 2009-10-27 | Archus Orthopedics, Inc. | Prostheses, tools and methods for replacement of natural facet joints with artifical facet joint surfaces |
US8409254B2 (en) | 2003-05-14 | 2013-04-02 | Gmedelaware 2 Llc | Prostheses, tools and methods for replacement of natural facet joints with artificial facet joint surfaces |
US8231655B2 (en) | 2003-07-08 | 2012-07-31 | Gmedelaware 2 Llc | Prostheses and methods for replacement of natural facet joints with artificial facet joint surfaces |
US8523907B2 (en) | 2003-07-08 | 2013-09-03 | Gmedelaware 2 Llc | Prostheses, tools and methods for replacement of natural facet joints with artificial facet joint surfaces |
EP2335654A1 (en) | 2003-11-25 | 2011-06-22 | Conformis, Inc. | Patient selectable knee joint arthoplasty devices |
US9056016B2 (en) | 2003-12-15 | 2015-06-16 | Gmedelaware 2 Llc | Polyaxial adjustment of facet joint prostheses |
US8187303B2 (en) | 2004-04-22 | 2012-05-29 | Gmedelaware 2 Llc | Anti-rotation fixation element for spinal prostheses |
US7406775B2 (en) | 2004-04-22 | 2008-08-05 | Archus Orthopedics, Inc. | Implantable orthopedic device component selection instrument and methods |
US8496687B2 (en) | 2004-04-22 | 2013-07-30 | Gmedelaware 2 Llc | Crossbar spinal prosthesis having a modular design and related implantation methods |
US8491635B2 (en) | 2004-04-22 | 2013-07-23 | Gmedelaware 2 Llc | Crossbar spinal prosthesis having a modular design and related implantation methods |
US7290347B2 (en) | 2004-04-22 | 2007-11-06 | Archus Orthopedics, Inc. | Facet joint prosthesis measurement and implant tools |
US8425557B2 (en) | 2004-04-22 | 2013-04-23 | Gmedelaware 2 Llc | Crossbar spinal prosthesis having a modular design and related implantation methods |
US7674293B2 (en) | 2004-04-22 | 2010-03-09 | Facet Solutions, Inc. | Crossbar spinal prosthesis having a modular design and related implantation methods |
US8675930B2 (en) | 2004-04-22 | 2014-03-18 | Gmedelaware 2 Llc | Implantable orthopedic device component selection instrument and methods |
US7670282B2 (en) | 2004-06-14 | 2010-03-02 | Pneumrx, Inc. | Lung access device |
US7775968B2 (en) | 2004-06-14 | 2010-08-17 | Pneumrx, Inc. | Guided access to lung tissues |
US7549984B2 (en) | 2004-06-16 | 2009-06-23 | Pneumrx, Inc. | Method of compressing a portion of a lung |
US7766891B2 (en) | 2004-07-08 | 2010-08-03 | Pneumrx, Inc. | Lung device with sealing features |
US7766938B2 (en) | 2004-07-08 | 2010-08-03 | Pneumrx, Inc. | Pleural effusion treatment device, method and material |
US8398681B2 (en) | 2004-08-18 | 2013-03-19 | Gmedelaware 2 Llc | Adjacent level facet arthroplasty devices, spine stabilization systems, and methods |
US8221461B2 (en) | 2004-10-25 | 2012-07-17 | Gmedelaware 2 Llc | Crossbar spinal prosthesis having a modular design and systems for treating spinal pathologies |
US10034999B2 (en) | 2004-11-23 | 2018-07-31 | Pneumrx, Inc. | Steerable device for accessing a target site and methods |
US9125639B2 (en) | 2004-11-23 | 2015-09-08 | Pneumrx, Inc. | Steerable device for accessing a target site and methods |
EP2324799A2 (en) | 2004-11-24 | 2011-05-25 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
US7914556B2 (en) | 2005-03-02 | 2011-03-29 | Gmedelaware 2 Llc | Arthroplasty revision system and method |
US8496686B2 (en) | 2005-03-22 | 2013-07-30 | Gmedelaware 2 Llc | Minimally invasive spine restoration systems, devices, methods and kits |
US8961516B2 (en) | 2005-05-18 | 2015-02-24 | Sonoma Orthopedic Products, Inc. | Straight intramedullary fracture fixation devices and methods |
US7942875B2 (en) | 2005-05-18 | 2011-05-17 | Sonoma Orthopedic Products, Inc. | Methods of using minimally invasive actuable bone fixation devices |
US8287541B2 (en) | 2005-05-18 | 2012-10-16 | Sonoma Orthopedic Products, Inc. | Fracture fixation device, tools and methods |
US7846162B2 (en) | 2005-05-18 | 2010-12-07 | Sonoma Orthopedic Products, Inc. | Minimally invasive actuable bone fixation devices |
US8287539B2 (en) | 2005-05-18 | 2012-10-16 | Sonoma Orthopedic Products, Inc. | Fracture fixation device, tools and methods |
US7914533B2 (en) | 2005-05-18 | 2011-03-29 | Sonoma Orthopedic Products, Inc. | Minimally invasive actuable bone fixation devices |
US9060820B2 (en) | 2005-05-18 | 2015-06-23 | Sonoma Orthopedic Products, Inc. | Segmented intramedullary fracture fixation devices and methods |
EP3187153A2 (en) | 2005-09-30 | 2017-07-05 | Conformis, Inc. | Bearing implant |
EP2520255A1 (en) | 2005-11-21 | 2012-11-07 | Vertegen, Inc. | Devices and methods for treating facet joints, uncovertebral joints, costovertebral joints and other joints |
EP2710967A2 (en) | 2006-02-06 | 2014-03-26 | ConforMIS, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9326780B2 (en) | 2006-02-06 | 2016-05-03 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief |
US9220516B2 (en) | 2006-02-06 | 2015-12-29 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
EP2671522A2 (en) | 2006-02-06 | 2013-12-11 | ConforMIS, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9220517B2 (en) | 2006-02-06 | 2015-12-29 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
EP2671521A2 (en) | 2006-02-06 | 2013-12-11 | ConforMIS, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9308053B2 (en) | 2006-02-06 | 2016-04-12 | Conformis, Inc. | Patient-specific joint arthroplasty devices for ligament repair |
EP2671520A2 (en) | 2006-02-06 | 2013-12-11 | ConforMIS, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
EP2649951A2 (en) | 2006-02-06 | 2013-10-16 | ConforMIS, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9474533B2 (en) | 2006-03-13 | 2016-10-25 | Pneumrx, Inc. | Cross-sectional modification during deployment of an elongate lung volume reduction device |
US8888800B2 (en) | 2006-03-13 | 2014-11-18 | Pneumrx, Inc. | Lung volume reduction devices, methods, and systems |
US9782558B2 (en) | 2006-03-13 | 2017-10-10 | Pneumrx, Inc. | Minimally invasive lung volume reduction devices, methods, and systems |
DE202007019683U1 (en) | 2006-03-13 | 2015-09-16 | PNEUMRX. lnc. | Minimally invasive lung volume reduction devices and systems |
US9801637B2 (en) | 2006-03-13 | 2017-10-31 | Pneumrx, Inc. | Genetically-associated chronic obstructive pulmonary disease treatment |
EP3143962A1 (en) | 2006-03-13 | 2017-03-22 | Pneumrx, Inc. | Minimally invasive lung volume reduction devices, methods, and systems |
US9402632B2 (en) | 2006-03-13 | 2016-08-02 | Pneumrx, Inc. | Lung volume reduction devices, methods, and systems |
EP3167821A1 (en) | 2006-03-13 | 2017-05-17 | PneumRx, Inc. | Lung volume reduction devices |
US10226257B2 (en) | 2006-03-13 | 2019-03-12 | Pneumrx, Inc. | Lung volume reduction devices, methods, and systems |
US9402633B2 (en) | 2006-03-13 | 2016-08-02 | Pneumrx, Inc. | Torque alleviating intra-airway lung volume reduction compressive implant structures |
US8932310B2 (en) | 2006-03-13 | 2015-01-13 | Pneumrx, Inc. | Minimally invasive lung volume reduction devices, methods, and systems |
US8157837B2 (en) | 2006-03-13 | 2012-04-17 | Pneumrx, Inc. | Minimally invasive lung volume reduction device and method |
US10188397B2 (en) | 2006-03-13 | 2019-01-29 | Pneumrx, Inc. | Torque alleviating intra-airway lung volume reduction compressive implant structures |
EP2842501A1 (en) | 2006-03-13 | 2015-03-04 | Pneumrx, Inc. | Minimally invasive lung volume reduction devices, methods, and systems |
US9402971B2 (en) | 2006-03-13 | 2016-08-02 | Pneumrx, Inc. | Minimally invasive lung volume reduction devices, methods, and systems |
US9155574B2 (en) | 2006-05-17 | 2015-10-13 | Sonoma Orthopedic Products, Inc. | Bone fixation device, tools and methods |
US8702755B2 (en) | 2006-08-11 | 2014-04-22 | Gmedelaware 2 Llc | Angled washer polyaxial connection for dynamic spine prosthesis |
US7909825B2 (en) | 2006-11-22 | 2011-03-22 | Sonoma Orthepedic Products, Inc. | Fracture fixation device, tools and methods |
US9259250B2 (en) | 2006-11-22 | 2016-02-16 | Sonoma Orthopedic Products, Inc. | Fracture fixation device, tools and methods |
US9931438B2 (en) * | 2008-01-28 | 2018-04-03 | Ngk Spark Plug Co., Ltd. | Article with foamed surface, implant and method of producing the same |
US10660990B2 (en) | 2008-01-28 | 2020-05-26 | Ngk Spark Plug Co., Ltd. | Article with foamed surface, implant and method of producing the same |
EP2848208A2 (en) | 2008-09-12 | 2015-03-18 | Pneumrx, Inc. | Minimally invasive lung volume reduction devices and their delivery |
US10058331B2 (en) | 2008-09-12 | 2018-08-28 | Pneumrx, Inc. | Enhanced efficacy lung volume reduction devices, methods, and systems |
WO2010030993A1 (en) | 2008-09-12 | 2010-03-18 | Pneumrx, Inc. | Improved and/or longer minimally invasive lung volume reduction devices and their delivery |
EP3305234A1 (en) | 2008-09-12 | 2018-04-11 | PneumRx, Inc. | Minimally invasive lung volume reduction devices and planning of their delivery |
US10285707B2 (en) | 2008-09-12 | 2019-05-14 | Pneumrx, Inc. | Enhanced efficacy lung volume reduction devices, methods, and systems |
US9192403B2 (en) | 2008-09-12 | 2015-11-24 | Pneumrx, Inc. | Elongated lung volume reduction devices, methods, and systems |
US9173669B2 (en) | 2008-09-12 | 2015-11-03 | Pneumrx, Inc. | Enhanced efficacy lung volume reduction devices, methods, and systems |
US9883870B2 (en) | 2009-02-24 | 2018-02-06 | Microport Orthopedics Holdings Inc. | Method for forming a patient specific surgical guide mount |
US10973536B2 (en) | 2009-02-24 | 2021-04-13 | Microport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US9675365B2 (en) | 2009-02-24 | 2017-06-13 | Microport Orthopedics Holdings Inc. | System and method for anterior approach for installing tibial stem |
US10660654B2 (en) | 2009-02-24 | 2020-05-26 | Microport Orthopedics Holdings Inc. | Method for forming a patient specific surgical guide mount |
US12256944B2 (en) | 2009-02-24 | 2025-03-25 | MicroPort Orthopedic Holdings, Inc. | Patient specific surgical guide locator and mount |
US9649117B2 (en) | 2009-02-24 | 2017-05-16 | Microport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US9642632B2 (en) | 2009-02-24 | 2017-05-09 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
US12220134B2 (en) | 2009-02-24 | 2025-02-11 | Microport Orthopedics Holdings Inc. | System for forming a patient specific surgical guide mount |
US11154305B2 (en) | 2009-02-24 | 2021-10-26 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US9901353B2 (en) | 2009-02-24 | 2018-02-27 | Microport Holdings Inc. | Patient specific surgical guide locator and mount |
US9566075B2 (en) | 2009-02-24 | 2017-02-14 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US11464527B2 (en) | 2009-02-24 | 2022-10-11 | Microport Orthopedics Holdings Inc. | Systems and methods for installing an orthopedic implant |
US9949747B2 (en) | 2009-02-24 | 2018-04-24 | Microport Orthopedics Holdings, Inc. | Systems and methods for installing an orthopedic implant |
US11911046B2 (en) | 2009-02-24 | 2024-02-27 | Microport Orthopedics Holdings, Inc. | Patient specific surgical guide locator and mount |
US10039557B2 (en) | 2009-02-24 | 2018-08-07 | Micorport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US10646238B2 (en) | 2009-02-24 | 2020-05-12 | Microport Orthopedics Holdings, Inc. | Systems and methods for installing an orthopedic implant |
US9017334B2 (en) | 2009-02-24 | 2015-04-28 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US11779347B2 (en) | 2009-02-24 | 2023-10-10 | Microport Orthopedics Holdings Inc. | System for forming a patient specific surgical guide mount |
US9089342B2 (en) | 2009-02-24 | 2015-07-28 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US11389177B2 (en) | 2009-02-24 | 2022-07-19 | Microport Orthopedics Holdings Inc. | Method for forming a patient specific surgical guide mount |
US9113914B2 (en) | 2009-02-24 | 2015-08-25 | Microport Orthopedics Holdings Inc. | Method for forming a patient specific surgical guide mount |
US11779356B2 (en) | 2009-02-24 | 2023-10-10 | Microport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US10512476B2 (en) | 2009-02-24 | 2019-12-24 | Microport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US11534186B2 (en) | 2009-02-24 | 2022-12-27 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
WO2010135352A1 (en) | 2009-05-18 | 2010-11-25 | Pneumrx, Inc. | Cross-sectional modification during deployment of an elongate lung volume reduction device |
EP2754419A2 (en) | 2011-02-15 | 2014-07-16 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs and related tools |
WO2013131066A1 (en) | 2012-03-02 | 2013-09-06 | Conformis, Inc. | Patient-adapted posterior stabilized knee implants, designs and related methods and tools |
US9486226B2 (en) | 2012-04-18 | 2016-11-08 | Conformis, Inc. | Tibial guides, tools, and techniques for resecting the tibial plateau |
US9675471B2 (en) | 2012-06-11 | 2017-06-13 | Conformis, Inc. | Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components |
WO2014151557A2 (en) | 2013-03-15 | 2014-09-25 | Pneumrx, Inc. | Torque alleviating intra-airway lung volume reduction compressive implant structures |
EP3632375A1 (en) | 2013-03-15 | 2020-04-08 | PneumRx Inc. | Torque alleviating intra-airway lung volume reduction compressive implant structures |
EP3357455A2 (en) | 2013-03-15 | 2018-08-08 | PneumRx, Inc. | Torque alleviating intra-airway lung volume reduction compressive implant structures |
US10537334B2 (en) | 2013-10-25 | 2020-01-21 | Pneumrx, Inc. | Genetically-associated chronic obstructive pulmonary disease treatment |
US9770278B2 (en) | 2014-01-17 | 2017-09-26 | Arthrex, Inc. | Dual tip guide wire |
US10390838B1 (en) | 2014-08-20 | 2019-08-27 | Pneumrx, Inc. | Tuned strength chronic obstructive pulmonary disease treatment |
WO2016046715A1 (en) * | 2014-09-25 | 2016-03-31 | Università Degli Studi Di Trento | Method for manufacturing porous scaffolds for biomedical uses and scaffolds thereof |
US10548648B2 (en) | 2014-09-30 | 2020-02-04 | Arthrex, Inc. | Intramedullary fracture fixation devices and methods |
US9814499B2 (en) | 2014-09-30 | 2017-11-14 | Arthrex, Inc. | Intramedullary fracture fixation devices and methods |
WO2016134409A1 (en) * | 2015-02-27 | 2016-09-01 | The University Of Sydney | Biomedical implantable materials |
EP3746139B1 (en) | 2018-02-02 | 2023-07-05 | Evonik Operations GmbH | Functionally graded polymer knee implant for enhanced fixation, wear resistance, and mechanical properties and the fabrication thereof |
CN111939319A (en) * | 2019-05-17 | 2020-11-17 | 北京化工大学 | A kind of bioactive porous polyetheretherketone and its preparation method and application |
US12108959B2 (en) | 2019-05-29 | 2024-10-08 | Wright Medical Technology, Inc. | Preparing a tibia for receiving tibial implant component of a replacement ankle |
CN111184913A (en) * | 2020-01-13 | 2020-05-22 | 吉林大学 | Artificial bone composite material based on polyether-ether-ketone and preparation method thereof |
CN111184913B (en) * | 2020-01-13 | 2021-06-04 | 吉林大学 | A kind of artificial bone composite material based on polyetheretherketone and preparation method thereof |
CN112972764A (en) * | 2021-03-19 | 2021-06-18 | 吉林大学 | Polyether-ether-ketone bone repair material with multi-scale holes and preparation method thereof |
CN113398328B (en) * | 2021-05-12 | 2022-08-12 | 上海云合景从新材料科技有限公司 | Porous polyether-ether-ketone and preparation method and application thereof |
CN113398328A (en) * | 2021-05-12 | 2021-09-17 | 上海云合景从新材料科技有限公司 | Porous polyether-ether-ketone and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
GB0015430D0 (en) | 2000-08-16 |
AU7432201A (en) | 2002-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002000275A1 (en) | Bio-compatible polymeric materials | |
US10660990B2 (en) | Article with foamed surface, implant and method of producing the same | |
WO2002000270A1 (en) | Bio-compatible polymeric materials | |
WO2002002158A1 (en) | Bio-compatible polymeric materials | |
US20070036844A1 (en) | Porous materials having multi-size geometries | |
CA2730771A1 (en) | Polymeric materials | |
JP2006512171A (en) | Reticulated elastomeric matrix, its manufacture and use in implantable devices | |
Wang et al. | Porous bioactive scaffold of aliphatic polyurethane and hydroxyapatite for tissue regeneration | |
JP2012505947A (en) | Polymer material | |
US12076463B2 (en) | Method of making an osteoconductive polymer article and an osteoconductive polymer article thus made | |
KR100737167B1 (en) | Method for preparing porous bone-cartilage composite scaffold for tissue engineering | |
Lu et al. | Controllable porosity hydroxyapatite ceramics as spine cage: fabrication and properties evaluation | |
KR100942822B1 (en) | Scaffolds for tissue regeneration comprising poly-paradioxanone-caprolactone copolymer | |
US8431623B2 (en) | Process for forming a porous PVA scaffold using a pore-forming agent | |
WO2003103925A1 (en) | Co-continuous phase composite polymer blends for in-vivo and in-vitro biomedical applications | |
TWI241199B (en) | Method for manufacturing porous bioresorbable material having interconnected pores | |
A Garcia-Gonzalez et al. | Patent survey on current applications of supercritical fluid technology in regenerative medicine | |
WO2002000271A1 (en) | Bio-compatible polymeric materials | |
Nandhini et al. | The importance of polymers in the preparation of medical devices for human body applications | |
WO2002049688A1 (en) | Bio-compatible polymeric materials | |
US20240197958A1 (en) | Hybrid, artificial bone tissue implant absorbing mechanical vibrations, whose architectural structure imitates trabecular bone, allowing the saturation of bone marrow, blood, and nutrients, supporting autological regeneration, which can be used with titanium structures | |
WO2002000762A1 (en) | Functionalised polymeric materials | |
WO2002000763A1 (en) | Bio-compatible polymeric materials | |
TWI445761B (en) | Biodegradable-bioresorbable composite and preparing method thereof | |
EP1559685A2 (en) | Devices that change size/shape via osmotic pressure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |